24/7 Market News Snapshot 30 September, 2025 – Silexion Therapeutics Corp Ordinary Shares (NASDAQ:SLXN)

September 30, 2025

DENVER, Colo., 30 September, 2025 (www.247marketnews.com) – (NASDAQ:SLXN) are discussed in this article.
Silexion Therapeutics Corp. is currently experiencing significant momentum in the market, as evidenced by a notable 10% increase in share price, climbing to $3.729 in pre-market trading. This rise follows a previous close of $3.390, with a trading volume reaching 3.54 million shares, highlighting a surge in investor interest. The positive shift in stock performance may reflect favorable news, particularly the recent announcement regarding the company’s lead candidate, SIL204.

Silexion has introduced compelling data showcasing SIL204’s efficacy in combating KRAS-driven cancers. In comprehensive studies, SIL204 demonstrated remarkable inhibition rates ranging from 83.5% to 99.7% across eleven human cancer cell lines representing five distinct cancer types. Notably, SIL204 achieved an inhibition rate of 89.2% in the SNU-601 cell line associated with gastric cancer, underscoring its potential for addressing challenging malignancies.

The breadth of SIL204’s efficacy positions it uniquely in the oncology landscape, with the capability to target difficult mutations such as G12R, which is prevalent in approximately 17% of pancreatic cancer cases. Ilan Hadar, Chairman and CEO, emphasized that the results affirm SIL204 as a pan-KRAS therapeutic candidate, potentially offering broader patient benefits compared to current therapies.

With solid preclinical findings to support its development, Silexion is preparing to advance SIL204 into Phase 2/3 clinical trials in the first half of 2026. Regulatory submissions are also being planned for both the European Union and additional health authorities, echoing Silexion’s commitment to delivering innovative RNA interference therapies aimed at enhancing oncology patient outcomes. As the company continues to forge ahead, these advancements signal a transformative potential for SIL204 in the competitive field of cancer therapeutics.

Related news for (SLXN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.